Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | TDP2 | O95551 | 2/20 | 0.49 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PTPRC | P08575 | 3/20 | 0.45 |
| ▸ | S100A4 | P26447 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22855674 | 0.84 | CYP3A4 (0.51) | CYP3A4TDP1CASP3TDP2CAPN9 | |
| SCHEMBL22855479 | 0.81 | CYP3A4 (0.49) | CYP3A4TDP1CASP3TDP2CAPN9 | |
| SCHEMBL429310 | 0.80 | MAPT (0.57) | CYP3A4TDP1CASP3TDP2CAPN9 | |
| Hydrochloric Acid SCHEMBL4967505 | 0.78 | MAPT (0.56) | CYP3A4TDP1CASP3TDP2CAPN9 | |
| SCHEMBL428211 | 0.78 | PARP10 (0.51) | CYP3A4MEN1KMT2ACA9CA1 | |
| SCHEMBL6902323 | 0.78 | ACHE (0.44) | TDP1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2144836 | 0.76 | TDP1 (0.57) | CYP3A4TDP1CASP3TDP2CAPN9 | |
| SCHEMBL21332980 | 0.76 | PARP10 (0.50) | TDP1TDP2MEN1KMT2AS100A4 | |
| SCHEMBL201301 | 0.76 | MAPT (0.54) | CYP3A4TDP1CASP3TDP2CAPN9 | |
| SCHEMBL6936653 | 0.76 | TDP2 (0.49) | CYP3A4TDP1CASP3TDP2CAPN9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438044-B1 | COMPOUNDS | JAPAN TOBACCO INC (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8399481-B2 | Compounds | XENTION LTD (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2438044-A1 | COMPOUNDS | Xention Limited (GB) | 2012-04-11 | — | — | EP | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-0999208-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND HYPERLIPEMIA REMEDY CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2000-05-10 | — | — | EP | disclosed |
| EP-0275888-B1 | Tricyclic benzimidazoles, process for their preparation and use as medicaments | BOEHRINGER MANNHEIM GMBH (DE) | 1994-04-06 | — | — | EP | disclosed |
| US-5116843-A | Anticoagulants, hypotensive agents and cardiovascular disorder | BOEHRINGER MANNHEIM GMBH (DE) | 1992-05-26 | — | — | US | disclosed |
| US-4954498-A | HYPOTENSIVE AGENTS, ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-09-04 | — | — | US | disclosed |
| EP-0275888-A2 | Tricyclic benzimidazoles, process for their preparation and use as medicaments | Roche Diagnostics GmbH (DE) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | CYP3A4 207/4885TDP1 799/4885CASP3 264/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | CYP3A4 237/4885TDP1 843/4885CASP3 156/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CYP3A4 67/4885TDP1 1883/4885CASP3 818/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | CYP3A4 67/4885TDP1 1883/4885CASP3 818/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | CYP3A4 385/4885TDP1 798/4885CASP3 831/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | CYP3A4 237/4885TDP1 843/4885CASP3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.